immun respons long maintain vaccin
base approach first suggest polio pioneer
immun respons founder jona salk use whole
inactiv aid virus inocul peopl
dread diseas complet safe compani
highlight safe complet test vaccin
human alreadi infect aid virus
mani medic communiti long disagre
believ glitch qualiti control
product vaccin factor make riski
mass-prevent strategi parallel often
note polio vaccin time given peopl
polio diseas
research use genet engin
synthet virus protein dr. salk chosen use live
virus kill gamma radiat
spokesman compani said intend
studi uninfect individu logist
issu involv product liabil work
first drag longer expect unclear
compani press forward studi
would launch clinic trial compani hiv vaccin
10 15 uninfect patient california cadr
patient would includ dr. salk
issu said brandon fradd biotechnolog
analyst montgomeri secur even virus
dead someon got hiv somehow infect
thing chanc happen extraordinarili
remot zero note batch virus
might proper inactiv mr. fradd add howev
compani main focus alway use
vaccin therapi individu alreadi infect
hiv
scott putney lead aid scientist alkerm
inc. say theoret possibl problem
could happen would rare event add
technolog make vaccin develop
point could assur great certainti
virus inactiv dr. putney say real
reserv killed-virus vaccin
simpli may work uninfect patient
immun respons spokesman stress focus
99 % effort far dedic toward
treatment alreadi infect patient san diego
compani product sale yet $ 4.3
million total research revenu 1991 clinic
trial work infect patient
late over-the-count trade immun respons share
quot $ 28.50 25 cent share
addit disclos delay clinic
trial immun respons yesterday announc
complet studi show certain method surrog
marker success identifi amount virus
present human blood higher virus quantiti
correl differ stage aid result
studi publish current issu aid research
human retrovirus give compani reliabl
benchmark measur progress lack patient
undergo clinic trial immun respons hiv vaccin
last novemb food drug administr advisori
panel said one surrog marker could use
sole indic regulatori approv clinic
indic typic involv longer trial period
would remain import factor immun respons
spokesman said compani hope marker combin
other studi would prompt fda reconsid
issu
